Completed End-of-Phase 2 meeting with the FDA; Company expects to provide a regulatory update in early 2Q 2026 and remains on track to initiate a Phase 3 study in chronic tetraplegia in mid-2026. Company expects to present clinical data from independent, blinded biomechanical gait analyses of the CONNECT SCI study in 2Q 2026, providing additional evidence with the potential to further support the systemic biological effect of NVG-291, differentiating genuine neural recovery from compensatory movement.Compan ...

Core Viewpoint - NervGen Pharma Corp. has announced its decision to voluntarily delist its common shares from the TSX Venture Exchange, effective March 16, 2026, to streamline operations and focus on clinical development for its lead therapeutic candidate, NVG-291 [1][2]. Group 1: Delisting Decision - The voluntary delisting reflects NervGen's maturity as it enters late-stage development for NVG-291 and aims to reduce costs and administrative burdens associated with maintaining a dual listing [2]. - The decision was approved by the Company's Board of Directors, and no shareholder approval is required due to the presence of an acceptable alternative market [4]. Group 2: Shareholder Impact - All shareholders, including Canadian shareholders, will retain full trading access to their common shares on Nasdaq, and no action is required from them regarding the delisting [3][7]. Group 3: Financial Program Termination - In connection with the delisting, the Company has terminated its at-the-market equity program, which had issued 245 common shares at a weighted average price of $6.20, resulting in aggregate net proceeds of $1,489 [5]. Group 4: Company Overview - NervGen Pharma is a clinical-stage biopharmaceutical company focused on developing neuroreparative therapeutics for spinal cord injury and other neurological conditions, with its lead candidate NVG-291 showing promise in clinical trials [6]. - NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the EMA, indicating its potential significance in treating spinal cord injuries [6].

Core Insights - NervGen Pharma Corp. has appointed Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as Senior Vice President, Patient Advocacy and Clinical Affairs, to strengthen its leadership team during a critical execution phase [1][2] Leadership Appointments - Shamim Ruff brings over 30 years of regulatory affairs experience, having previously held leadership roles at Stoke Therapeutics and Sarepta Therapeutics, and will oversee NervGen's regulatory strategy [2][3] - Christine McSherry has more than 30 years of experience in patient advocacy and clinical development, previously co-founding Casimir, a clinical research organization, and will ensure the voice of the spinal cord injury (SCI) community is central to NervGen's clinical strategy [3][4] Product Development - NVG-291, NervGen's lead therapeutic candidate, is a neuroreparative peptide that has shown promising clinical data in the Phase 1b/2a CONNECT SCI Study, indicating evidence of nervous system repair [3][6] - The CONNECT SCI Study is ongoing for individuals with subacute SCI, and preparations for a Phase 3 clinical trial in chronic SCI are underway [6] Regulatory Designations - NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency (EMA) for the treatment of SCI, highlighting its potential as a first pharmacologic treatment for this condition [6]

Core Insights - NervGen Pharma Corp. is a clinical-stage biopharmaceutical company focused on developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic conditions [5] Upcoming Investor Conferences - NervGen's executive leadership team, including CEO Adam Rogers, will participate in multiple investor conferences in 2026 [1] - The Oppenheimer 36th Annual Healthcare Life Sciences Conference will take place on February 25-26, 2026, with NervGen's presentation scheduled for February 25 from 12:40 to 1:10 pm ET [2] - The TD Cowen 46th Annual Health Care Conference is set for March 2-4, 2026, with NervGen presenting on March 2 from 2:30 to 3:00 pm ET [3] - The Leerink Partners Global Healthcare Conference will occur from March 8-11, 2026, featuring 1x1 investor meetings [4] Company Overview - NervGen's lead therapeutic candidate, NVG-291, is a subcutaneously administered neuroreparative peptide that has shown durable improvement in function and quality of life in individuals with chronic spinal cord injury [5] - NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the EMA for treating spinal cord injury [5] - The company is also developing a next-generation candidate, NVG-300, aiming to transform treatment paradigms for neurotraumatic and neurologic conditions with significant unmet medical needs [5]

Core Viewpoint - NervGen Pharma Corp. announced the retirement of Chief Financial Officer Bill Adams, effective March 15, 2026, and has engaged an executive search firm to find a successor while Mr. Adams will continue to support the company in an advisory role post-retirement [1][2] Company Overview - NervGen Pharma Corp. is a clinical-stage biopharmaceutical company focused on developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions [3] - The company's mission is to transform the lives of individuals living with SCI by enabling the nervous system to repair itself [3] - NervGen's lead therapeutic candidate, NVG-291, is a subcutaneously administered neuroreparative peptide that has shown durable improvement in function, independence, and quality of life in clinical studies [3] Clinical Development - NVG-291 was evaluated in the Phase 1b/2a CONNECT SCI Study for individuals with chronic SCI, and the study demonstrated significant therapeutic potential [3] - The company is currently conducting an ongoing Phase 1b/2a CONNECT SCI Study for individuals with subacute SCI and is preparing for a Phase 3 clinical trial in chronic SCI [3] - NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency (EMA) for the treatment of SCI [3] Leadership Transition - Adam Rogers, President and CEO of NervGen, expressed gratitude for Bill Adams' leadership and contributions over the past six years, highlighting the company's transformation during his tenure [2] - Mr. Adams noted his pride in the financial and operational foundation built at NervGen and expressed confidence in the company's future [2]

Core Insights - NervGen Pharma Corp. is set to present clinical data from the Phase 1b/2a CONNECT SCI Study, highlighting durable improvements in function, independence, and quality of life for individuals with chronic spinal cord injury [1] - The presentation will take place at the Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium, scheduled for February 15-17, 2026, in Washington, DC [1][2] Company Overview - NervGen Pharma is a clinical-stage biopharmaceutical company focused on developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic conditions [4] - The company's lead therapeutic candidate, NVG-291, is a subcutaneously administered neuroreparative peptide that has shown durable improvement in function and quality of life in chronic spinal cord injury patients [4] - NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the EMA for the treatment of spinal cord injury [4] Event Details - The presentation titled "Emerging Therapies with Challenges and Opportunities for the Future" will include a panel discussion and is scheduled for February 15, 2026, from 4:15-5:00 pm ET [2] - Key participants in the panel include experts from Lifeward and the FDA, indicating a collaborative approach to addressing spinal cord injury [2] Industry Context - Unite2Fight Paralysis is a nonprofit organization aimed at uniting the spinal cord injury community to advocate for research and treatment options [3] - The Annual Science and Advocacy Symposium serves as a central forum for stakeholders in the spinal cord injury community, promoting collaboration among scientists, clinicians, and policymakers [3]

Core Viewpoint - NervGen Pharma Corp. has appointed Dr. Adam Rogers as President and CEO, reflecting the Board's confidence in his leadership and vision for the company's future in neuroreparative therapeutics for spinal cord injury [1][2][3] Company Leadership - Dr. Rogers has been recognized for his decisive execution during his tenure as Interim CEO, including the successful Nasdaq listing and positioning of NVG-291 for late-stage development [2][3] - The Board believes Dr. Rogers embodies the leadership qualities necessary for advancing novel therapies, emphasizing his background as a physician and biotech executive [3] Company Mission and Product Development - NervGen's mission is to transform the lives of individuals with spinal cord injuries by enabling the nervous system to repair itself [6][7] - The lead therapeutic candidate, NVG-291, has shown durable improvement in function and quality of life in clinical studies and is preparing for a Phase 3 trial [7] - NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the EMA, highlighting its potential in addressing significant unmet medical needs [7] Stock Options and Compensation - In connection with Dr. Rogers' appointment, the company granted 717,891 stock options, with specific vesting schedules and exercise prices [3]

Core Viewpoint - NervGen Pharma Corp. has appointed Dr. Adam Rogers as President and CEO, reflecting the Board's confidence in his leadership and vision for the company's future in neuroreparative therapeutics for spinal cord injury [1][2][3] Company Leadership - Dr. Rogers has been recognized for his decisive execution during his tenure as Interim CEO, including the successful Nasdaq listing and positioning of NVG-291 for late-stage development [2][3] - The Board believes Dr. Rogers embodies the leadership qualities necessary for advancing novel therapies, combining his experience as a physician and biotech executive [3] Company Mission and Vision - The company aims to transform the lives of individuals with spinal cord injuries by enabling the nervous system to repair itself, with NVG-291 as its lead therapeutic candidate [6][7] - Dr. Rogers emphasizes a mission-driven commitment to achieving meaningful progress for patients and communities affected by spinal cord injuries [3] Stock Options and Compensation - In connection with Dr. Rogers' appointment, the company granted 717,891 stock options, with specific vesting schedules and exercise prices [3] Background of Dr. Adam Rogers - Dr. Rogers has been on NervGen's Board since July 2022 and has a background in ophthalmology and biotechnology, having co-founded Hemera Biosciences and served as CEO [4][5]

Core Viewpoint - NervGen Pharma Corp. is set to ring the closing bell at the Nasdaq Stock Market on January 22, 2026, marking a significant milestone in the company's growth and evolution as a clinical-stage biopharmaceutical company focused on neuroreparative therapeutics for spinal cord injury and other neurological conditions [1][3]. Company Overview - NervGen Pharma Corp. is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics aimed at transforming the lives of individuals with spinal cord injury (SCI) by enabling the nervous system to repair itself [4]. - The company's lead therapeutic candidate, NVG-291, is a subcutaneously administered neuroreparative peptide that has shown durable improvement in function, independence, and quality of life in individuals with chronic SCI [4]. - NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency (EMA) for the treatment of SCI, with ongoing enrollment in a Phase 1b/2a clinical study and preparations for a Phase 3 trial [4]. Leadership and Recognition - Adam Rogers, MD, Chairman and Interim Chief Executive Officer, emphasized the honor of participating in the Nasdaq closing bell ceremony and acknowledged the support from shareholders, collaborators, and families involved in clinical research [3]. - The event will be livestreamed from the Nasdaq MarketSite Tower, showcasing the company's mission and achievements to a broader audience [3].

Core Viewpoint - NervGen Pharma Corp. has received approval for its common shares to be listed on Nasdaq, marking a significant milestone in its development as a biopharmaceutical company focused on neuroreparative therapeutics for spinal cord injury and other neurological conditions [1] Company Overview - NervGen Pharma is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics aimed at transforming the lives of individuals with spinal cord injury (SCI) [2] - The lead therapeutic candidate, NVG-291, is a subcutaneously administered neuroreparative peptide that has shown durable improvements in function, independence, and quality of life in chronic SCI patients [2] - NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency for the treatment of SCI [2] Recent Developments - The listing on Nasdaq is expected to enhance market visibility, improve liquidity, and broaden the shareholder base, ultimately driving long-term shareholder value as the company advances NVG-291 [1] - Recent Phase 1b/2a CONNECT SCI Study data revealed unprecedented durable improvements in function and quality of life for individuals with chronic SCI, with significant enhancements in upper-limb corticospinal signaling [1] - The company plans to conduct a U.S. FDA End-of-Phase 2 meeting in early 2026 to discuss the development and registration pathway for NVG-291 [1]